COMPOUNDS FOR INHIBITING KINASE EGFR, METHODS FOR PRODUCTION AND USE THEREOF Russian patent published in 2025 - IPC C07D471/06 A61K31/506 A61P35/00 A61P35/02 

FIELD: chemistry; pharmaceutics.

SUBSTANCE: invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof. In formula (I): X is selected from a group consisting of N and CH; R₁ is hydrogen; R₂ is selected from the group consisting of C1-6 alkyl, deuterated C1-6 alkyl, C3-6 cycloalkyl and C1-6 haloalkyl; R₃ is -NR₉(CH₂)₂NR₉’R₉’’; R₄ is ; R₅, R₆ and R₇ are independently selected from the group consisting of hydrogen and halogen; R₈ is selected from the group consisting of hydrogen, C1-6 alkyl and C1-6 haloalkyl; R 9 is selected from a group consisting of hydrogen, C1-6 alkyl, deuterated C1-6 alkyl and C1-6 haloalkyl; R₉' and R₉'' are independently selected from the group consisting of hydrogen, C1-6 alkyl, C3-6 cycloalkyl, deuterated C1-6 alkyl and C1-6 haloalkyl, or R₉' and R₉'' together with a nitrogen atom bonded thereto, form a heterocycle, said heterocycle is unsubstituted or optionally substituted with 1–3 groups selected from the group consisting of halogen, C1-6 alkyl, C1-3 alkoxy, methylthio, methanesulfonyl and C1-6 haloalkyl; R₁₀ is hydrogen and R₁₁ is hydrogen.

EFFECT: disclosed compounds can selectively inhibit the activity of epidermal growth factor receptor (EGFR) mutants, demonstrate a high inhibitory effect on the EGFR mutant and antiproliferative activity against cancer cells and can be used for treating cancer.

2 cl, 1 dwg, 7 tbl, 1 ex